$4.830
-0.098 (-2.03%)收盘时
TLSI 资讯
TLSI 事件
TriSalus Reports Q2 Revenue of $11.4M, Exceeding Expectations
Reports Q2 revenue $11.4M, consensus $10.27M. "We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion and adoption of the TriNav platform, and generated clinical evidence that demonstrates and validates the value of our technology," said Mary Szela, President and Chief Executive Officer of TriSalus. "We also wanted to acknowledge the Centers for Medicare and Medicaid Services on the recent establishment of a G-code that extends reimbursement for vascular embolization procedures with the use of a pressure-generating catheter into the physician office-based lab site of service. We look forward to maintaining an active dialogue with CMS as their team finalizes the reimbursement rate in the coming months.
Company Maintains 2026 Revenue Guidance of $54M-$57M
The Company is maintaining its full-year 2026 revenue guidance of $54M-$57M, consistent with the range set in the first quarter and representing growth of 19% to 26% compared to full year 2025.
TriSalus Q1 Revenue at $8.9M, Below Consensus
Reports Q1 revenue $8.9M, consensus $10.4M. "The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our commercial infrastructure, expanded the clinical evidence supporting PEDD, and continued advancing our next-generation platform opportunities," said Mary Szela, President and Chief Executive Officer of TriSalus. "We are increasingly demonstrating that PEDD is not simply a device, but a differentiated therapeutic delivery platform capable of improving procedural outcomes, reducing healthcare utilization, and expanding treatment possibilities across multiple indications. During and subsequent to the quarter, we added meaningful new clinical evidence supporting PEDD across liver embolization therapy for liver cancer, and other new embolization applications, including one of the largest real-world analyses ever conducted in interventional oncology. At the same time, we substantially completed the commercial expansion initiatives designed to support our next phase of growth and broader market penetration. Our updated revenue outlook reflects the lower Q1 revenue from the commercial expansion and the delayed FDA clearance timing for TriNav Advance, our next-generation device which extends PEDD capability to small distal vessels via microcatheter. We continue to believe the long-term growth opportunity for the PEDD platform remains substantial."
TriSalus Life Sciences Appoints Richard Marshall as Chief Medical Officer
TriSalus Life Sciences announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company's medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.
TriSalus Q4 Revenue Reaches $13.205M, Exceeds 2025 Guidance
Reports Q4 revenue $13.205M vs $8.261M last year. "During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, President and CEO of TriSalus. "We are pleased to have exceeded our 2025 revenue guidance of 50%, delivering 53%, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。